ASCO: AstraZeneca’s ADRIATIC Passes One Test, With One More To Go
The results for Imfinzi mark the first significant advance in LS-SCLC in four decades, but will the combination with Imjudo succeed after flopping in CASPIAN?
The results for Imfinzi mark the first significant advance in LS-SCLC in four decades, but will the combination with Imjudo succeed after flopping in CASPIAN?